Table 2

Treatment-emergent adverse events occurring in ≥3% of patients in any group and all serious adverse events

Embedded Image

  • *Grade 3 (placebo); grades 1, 2 and 3 (mavrilimumab 150 mg).

  • †One non-serious pneumonia was reported in the placebo group.

  • eow, every other week.